

RISK MANAGEMENT

- RM 1: Regulatory Compliance and Internal Controls
 - RM 1-1: Regulatory Compliance Management
- RM 2: Regulatory Compliance
 - RM 2-1: Maintaining Compliance
- RM 3: Information Systems
 - RM 3-1: Information Systems Management
 - RM 3-2: Systems Risk Assessment
- RM 4: Business Continuity
 - RM 4-1: Business Continuity Plan

OPERATIONS AND INFRASTRUCTURE

- OPIN 1: Business Management
 - OPIN 1-1: Policy and Process Maintenance
 - OPIN 1-2: Delegation Management
- OPIN 2: Staff Management
 - OPIN 2-1: Clinical Staff Credentialing
 - OPIN 2-2: Employment Screening
 - OPIN 2-3: Staff Training Programs
 - OPIN 2-4: Code of Ethical Conduct
 - OPIN 2-5: Employee Diversity, Equity and Inclusion
- OPIN 3: Clinical Leadership
 - OPIN 3-1: Clinical Staff Leadership

PERFORMANCE MONITORING AND IMPROVEMENT

- PMI 1: Quality Management Scope
 - PMI 1-1: Quality Structure
- PMI 2: Quality Data Collection and Evaluation
 - PMI 2-1: Data Collection and Evaluation

CONSUMER PROTECTION AND EMPOWERMENT

- CPE 1: Protection of Consumer Information
 - CPE 1-1: Privacy and Security of Consumer Information
- CPE 2: Consumer Safeguards and Communication
 - CPE 2-1: Consumer Diversity, Equity and Inclusion
 - CPE 2-2: Consumer Safety Protocols
 - CPE 2-3: Consumer Complaint Process
 - CPE 2-4: Health Literacy Promotion
 - CPE 2-5: Consumer Marketing Safeguards
- CPE-HP 3: (Not Applicable)
- CPE-HP 4: Financial Incentives
 - CPE-HP 4-1: Monitoring Financial Incentives

UTILIZATION MANAGEMENT

- UM 1: Program Management
 - UM 1-1: Program Management
 - UM 1-2: Utilization Review Monitoring
- UM 2: Clinical Review Criteria
 - UM 2-1: Review Criteria Requirements
- UM 3: (Not Applicable)
- UM 4: Limitations of Initial Screening
 - UM 4-1: Initial Screening Policy
- UM 5: Initial Screening Process
 - UM 5-1: Initial Screening Staff Resources
 - UM 5-2: Non-Clinical Staff Provide Administrative Support
- UM 6: Limitations of Initial Clinical Review
 - UM 6-1: Initial Clinical Review Policy
 - UM 6-2: Automated-Only Review
 - UM 6-3: Initial Clinical Reviewer Licensure
- UM 7: AI and ML Medical Software Selection Criteria
 - UM 7-1: AI and ML Medical Software Used in Utilization Review

- UM 8: Initial Clinical Review Process
 - UM 8-1: Initial Clinical Reviewer Resources
- UM 9: Clinical Peer Review
 - UM 9-1: Clinical Peer Review Policy
- UM 10: Clinical Peer Review Qualifications
 - UM 10-1: Clinical Peer Reviewer Licensure
 - UM 10-2: Additional Clinical Peer Reviewer Qualifications
- UM 11: Clinical Peer Review Process
 - UM 11-1: Peer-to-Peer Conversation
- UM 12: Utilization Review Timelines and Notification
 - UM 12-1: Utilization Review Notification Time Frames
 - UM 12-2: Lack of Information Policy
 - UM 12-3: Information Upon Which to Base Review Determinations
 - UM 12-4: Certification Decision Notice
 - UM 12-5: Written Notice of Non-Certification Decisions
- UM 13: Utilization Review Appeals
 - UM 13-1: Appeal Policy
- UM 14: Appeal Reviewer Qualifications
 - UM 14-1: Appeal Peer Reviewer Licensure
 - UM 14-2: Additional Appeal Peer Reviewer Qualifications
 - UM 14-3: Additional Appeal Peer Reviewer Requirements
- UM 15: (Not Applicable)
- UM 16: Appeals
 - UM 16-1: Appeal Process
 - UM 16-2: Appeal Notification Time Frames
 - UM 16-3: Written Notice of Non-Certifications Upheld on Appeal
- UM 17: Drug Utilization Management
 - UM 17-1: Initial Determinations
 - UM 17-2: Initial Denial and Appeal Determinations